Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System)

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 9, 2011, Pages 930-938

  Guzek, Markus ^a,b   Zorina, Olesya I ^a   Semmler, Alexander ^c   Gonzenbach, Roman R ^c   Huber, Martin ^a   Kullak Ublick, Gerd A ^a,d   Weller, Michael ^c   Russmann, Stefan ^a,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Psychiatric Services Aargau   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adverse drug reactions; Clinical decision support software; Clinical management; Drug interactions; Drug safety; Neurology

Indexed keywords

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DECISION SUPPORT SYSTEM; DRUG INTERACTION; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; TERTIARY HEALTH CARE;

CENTRAL NERVOUS SYSTEM DISEASES; CROSS-SECTIONAL STUDIES; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG INTERACTIONS; HUMANS; INPATIENTS; RETROSPECTIVE STUDIES; RISK FACTORS; SOFTWARE;

EID: 80052348086     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2197     Document Type: Article

References (33)

1. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277(4): 307-311.
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277(4): 301-306.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-1205.
4. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15-19.
5. Gurwitz J, Field T, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118(3): 251-258.
6. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 2003; 163(12): 1409-1416.
7. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 2005; 293(10): 1223-1238.
8. Smith DH, Perrin N, Feldstein A, et al. The impact of prescribing safety alerts for elderly persons in an electronic medical record: an interrupted time series evaluation. Arch Intern Med 2006; 166(10): 1098-1104.
9. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001; 286(22): 2839-2844.
10. Sheen SS, Choi JE, Park RW, Kim EY, Lee YH, Kang UG. Overdose Rate of Drugs Requiring Renal Dose Adjustment: Data Analysis of 4Years Prescriptions at a Tertiary Teaching Hospital. J Gen Intern Med 2008; 23(4): 423-428.
11. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40(12): 1161-1171.
12. Hansten PD. Drug interaction management. Pharm World Sci 2003; 25(3): 94-97.
13. Shah NR. Improving Acceptance of Computerized Prescribing Alerts in Ambulatory Care. J Am Med Inform Assoc 2005; 13(1): 5-11.
14. Mannheimer B, Ulfvarson J, Eklof S, Bergqvist M, von Bahr C. A clinical evaluation of the Janus Web Application, a software screening tool for drug-drug interactions. Eur J Clin Pharmacol 2008; 64(12): 1209-1214.
15. van der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 2006; 13(2): 138-147.
16. Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 2003; 163(21): 2625-2631.
17. Lin CP, Payne TH, Nichol WP, Hoey PJ, Anderson CL, Gennari JH. Evaluating clinical decision support systems: monitoring CPOE order check override rates in the Department of Veterans Affairs' Computerized Patient Record System. J Am Med Inform Assoc 2008; 15(5): 620-626.
18. Hansten PD, Horn JR, Hazlet TK. ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc (Wash) 2001; 41(2): 161-165.
19. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 2004; 44(2): 142-151.
20. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash) 2001; 41(2): 200-204.
21. Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE, Armstrong EP. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm 2006; 12(5): 383-389.
22. Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother 2010; 44(1): 28-34.
23. Aronoff GR, Bennett WM, Berns JS. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children (5th edn). ACT Press, 2007.
24. MediQ. [computer program] [program]. Psychiatrische Dienste Aargau AG: Brugg, 2010.
25. Hansten PD, Horn JR. Drug interactions: analysis and management. Wolters Kluwer Health: St. Louis, MO, Facts & Comparisons, 2010.
26. Baxter K, Stockley IH. Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance, and management. 9th ed. Pharmaceutical Press: London; Chicago, 2010.
27. Lin CP, Nichol WP, Hoey P, et al. Approach for analysis of order check overrides in a computerized practitioner order entry system. AMIA Annu Symp Proc 2005: 1033.
28. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37(3): 253-257.
29. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352(10): 969-977.
30. Fulda TR, Valuck RJ, Vander Zanden J, Parker S, Byrns PJ, Utilization UPD. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res Clin Exp 2000; 61(8): 540-548.
31. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004; 44(2): 136-141.
32. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007; 63(6): 709-714.
33. Smithburger PL, Kane-Gill SL, Benedict NJ, Falcione BA, Seybert AL. Grading the Severity of Drug-Drug Interactions in the Intensive Care Unit: A Comparison Between Clinician Assessment and Proprietary Database Severity Rankings. Ann Pharmacother 2010; 44(11): 1718-1724.